Thermo Fisher Scientific Inc
TMO
Positions held
Your positionsTMO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Thermo Fisher Scientific is well-positioned in the growing diagnostics and research industry, benefiting from increasing demand for healthcare solutions.
- Revenue increased by 9% compared to the prior quarter, reaching $12.0 billion.
- Gross margin improved to 40.7%, up from 40.3% in the previous quarter.
- The company's high debt-to-equity ratio of 80.575 may pose risks in a rising interest rate environment.
- Trailing P/E ratio stands at 35.34, indicating the stock may be overvalued compared to historical averages.
- Operating margin decreased slightly to 18.22% in the latest quarter from 18.85% in the previous quarter.
Fundamentals
| Market cap | $241.07B | Enterprise value | $279.68B | Trailing P/E | 35.09 | Forward P/E | 23.64 |
| PEG | 1.97 | Price / book | 4.58 | Beta | 0.88 | Dividend yield | 0.29% |
| Revenue growth | 10.5% | Earnings growth | 9.4% | Gross margin | 41.0% | Operating margin | 18.8% |
| Profit margin | 15.0% | ROE | 13.5% | ROA | 5.1% | Debt / equity | 0.81 |
| Current ratio | 1.55 | Free cash flow | $6.24B | Analyst recommendation | strong_buy | Mean target | $673.44 |
| 52w high | $694.33 | 52w low | $435.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $12.0B | $11.0B | $12.2B | $11.1B | $10.9B |
| Op margin | 18.2% | 17.4% | 18.9% | 18.7% | 17.7% |
| Net income | $1.7B | $1.7B | $2.0B | $1.6B | $1.6B |
| Gross margin | 40.7% | 40.3% | 41.0% | 41.2% | 40.6% |
| Gross profit | $4.9B | $4.4B | $5.0B | $4.6B | $4.4B |
| Operating income | $2.2B | $1.9B | $2.3B | $2.1B | $1.9B |
- Revenue +9% vs prior quarter ($12.0B vs $11.0B).
- Gross margin 40.7% (was 40.3% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $44.6B | $42.9B | $42.9B | $44.9B |
| Op margin | 18.2% | 18.0% | 17.1% | 18.9% |
| Net income | $6.7B | $6.3B | $6.0B | $7.0B |
| Gross margin | 40.9% | 41.3% | 39.9% | 42.2% |
| Gross profit | $18.2B | $17.7B | $17.1B | $19.0B |
| Operating income | $8.1B | $7.7B | $7.3B | $8.5B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · What Could Thermo Fisher Scientific (TMO) Change With Its New Digital CMC Consortium?
2026-10-08 · Why Thermo Fisher Scientific (TMO) Is Back In The Spotlight
2026-10-08 · Baird Adjusts Price Target on Thermo Fisher Scientific to $723 From $686
2026-10-07 · Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
2026-10-07 · Evercore ISI Adjusts Thermo Fisher Scientific Price Target to $690 From $570
2026-10-07 · Is This the Right Time to Add TMO Stock to Your Portfolio?
2026-10-06 · JPMorgan reveals stocks worth buying in October 2026
2026-10-06 · Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
2026-10-06 · Barclays Adjusts Thermo Fisher Scientific Price Target to $750 From $650, Maintains Overweight Rating
Price (daily)
Full chart · RSI · MACD · patterns